ACHN

Achillion Reports Third Quarter and Nine Month 2012 Financial Results

[at noodls] – NEW HAVEN, Conn., Nov. 8, 2012 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and nine months ended September 30, 2012. For the third quarter … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: BioCryst, Presidio Merger Creates Yet Another Competitor in the HCV Segment

[ACN Newswire] – By Jake KingIn an all-stock merger announced Thursday morning, BioCryst Pharmaceuticals (NASDAQ:BCRX) will acquire privately-held Presidio, Inc, creating a new business entity to focus on oral Hepatitis … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: Abbot’s Impressive HCV Data Continues the Trend; Everyone’s Got a Candidate

[ACN Newswire] – By Jake KingDevelopers of potential Hepatitis C (HCV) treatments are among the most-traded in the healthcare industry on Monday, following an announcement from Abbot Laboratories (NYSE:ABT) that a combinations … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: ACHN Keeps Advancing, Visibility As Leader In Next-Gen HCV Drugs Increases

[ACN Newswire] – By David MoskowitzAchillion Pharmaceuticals (NASDAQ:ACHN) is up nearly 80% since its summer lows (see our initial article here ), as the hepatitis C (HCV) space continues to evolve. While Gilead’s (NASDAQ:GILD) … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboard […]